Search results
Results from the WOW.Com Content Network
Genzyme (also known as Genzyme Transgenics Corp or GTC Biotherapeutics) was an American biotechnology company based in Cambridge, Massachusetts. From its acquisition in 2011 to 2022 Genzyme operated as a fully owned subsidiary of Sanofi. In 2010, Genzyme was the world's third-largest biotechnology company, employing more than 11,000 people ...
French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right ...
In 2014, Sanofi Genzyme acquired a 12 percent stake in Alnylam and increased its rights to several of the company's drugs for $700 million. In a separate transaction Alnylam announced that it had purchased Merck & Co.'s Sirna Therapeutics, for $25 million cash and $150 million in stock.
The company is developing ALN-TTR in collaboration with Genzyme, a subsidiary of Sanofi, with an upfront payment of $22.5 million and nearly $50 million in milestones. ALN-TTR02 recently received ...
It seems that months of contentious merger talks between French pharmaceutical company Sanofi-Aventis (SNY) and U.S. biotech Genzyme (GENZ) have entered the home stretch. Sanofi is expected to ...
Sanofi lifted its 2018 profit target for the second time this year after robust sales of its vaccines and rare diseases division, Genzyme, helped it beat third-quarter profit expectations. The ...
In the spring of 2014, Aastrom Bio acquired Sanofi's cell therapy and regenerative medicine business which Sanofi had acquired when purchasing Genzyme in 2011. [1] This transformed Aastrom in several ways: it increased the employee count by 8-fold and provided a revenue stream and products to market, which it had not had before.
Sanofi-Aventis (SNY) CEO Chris Viehbacher (pictured) said in a webcast Wednesday he believes his French pharmaceutical company will eventually buy U.S. biotech company Genzyme (GENZ) at a ...